Neogen vs Bio-Techne
NEOG and TECH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NEOG and TECH compare
Bio-Techne is the larger company, worth 4.5 times as much as Neogen ($11.4B against $2.5B).
Bio-Techne grew revenue faster over the last twelve months (0.94% versus −0.33% for Neogen).
Bio-Techne pays a dividend yielding 0.44%; Neogen does not pay one.
Bio-Techne scores higher on the StockData Score (11 against 7 for Neogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NEOG | TECH |
|---|---|---|
| Size and price | ||
| Market cap | $2.5B | $11.4B |
| Share price | $11.60 | $72.80 |
| Change, 1 year | 82.4% | 26.7% |
| Change, 5 years | −73.6% | −41.9% |
| Beta (5Y) | 1.20 | 1.07 |
| Employees | 2,636 | 3,000 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 66.8× |
| P/S | 2.9× (better) | 9.3× |
| P/B | 1.2× (better) | 5.3× |
| EV/EBITDA | 35.9× | 33.4× (better) |
| P/FCF | 50.9× | 37.1× (better) |
| FCF yield | 2.0% | 2.7% (better) |
| Fair value | $7.55 | $52.06 |
| Margin of safety | −53.7% | −39.8% (better) |
| Growth | ||
| Revenue growth (TTM) | −0.33% | 0.94% (better) |
| Revenue growth, 5Y average | 13.2% (better) | 5.5% |
| EPS growth (TTM) | – | 122% |
| EPS growth, 5Y average | – | 5.9% |
| Profitability | ||
| Gross margin | 47.4% | 65.8% (better) |
| Operating margin | −0.83% | 19.6% (better) |
| Net margin | −6.3% | – |
| FCF margin | 5.6% | 25.1% (better) |
| Return on equity | −2.7% | – |
| Return on invested capital | −0.17% | 8.8% (better) |
| Financial health | ||
| Debt / equity | 0.74 | 0.09 (better) |
| Net debt / EBITDA | 12.69 (better) | −0.44 |
| Interest coverage | – | 27.2× |
| Current ratio | 3.90 (better) | 2.28 |
| Altman Z-score | 1.43 | 16.15 (better) |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | – | 0.44% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Shareholder yield | 0.00% | 0.44% (better) |
| Ownership | ||
| Held by institutions | 109% | 112% |
| Held by insiders | 0.60% | 0.36% |
| Insider net buying, 12 months | −$102K (better) | −$437K |
| Superinvestors holding | – | 4 |
| Short interest, % of float | 5.9% | 4.9% |
Go deeper
- NEOG stock overview
- NEOG income statement
- NEOG valuation and score
- TECH stock overview
- TECH income statement
- TECH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.